On May 23, 2024, Radar Therapeutics Inc closed the transaction. The company received $13,400,000 in a round of funding led by a new investor, NFX Capital Management, LLC. The transaction included participation from new investors, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
881.5 USD | -1.12% | -0.04% | +51.47% |
07:34pm | Eli Lilly to 'Continue to Pursue Legal Remedies' Over Tirzepatide Product Claims | MT |
07:12pm | Eli Lilly Calls Out Unsafe Practices Involving Diabetes, Obesity Drugs | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.47% | 803B | |
-5.57% | 351B | |
+19.60% | 324B | |
+11.37% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+7.52% | 164B | |
-3.20% | 155B | |
-1.84% | 117B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Radar Therapeutics announced that it has received $13.4 million in funding from NFX Capital Management, LLC, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors